<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Properties of Repurposed Drugs for COVID-19
   <xref rid="tblfn1" ref-type="table-fn">a</xref>
  </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Drug</th>
    <th>Brand Name</th>
    <th>Mechanism of Action</th>
    <th>Main Indication</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="4">
     <bold>Antivirals</bold>
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <hr/>
    </td>
   </tr>
   <tr>
    <td>Danoprevir</td>
    <td>Ganovo</td>
    <td>NS3/4A protease inhibitor</td>
    <td>HCV</td>
   </tr>
   <tr>
    <td>Favipiravir</td>
    <td>Avigan</td>
    <td>Nucleoside analog</td>
    <td>Broad-spectrum antiviral</td>
   </tr>
   <tr>
    <td>Lopinavir/ritonavir</td>
    <td>Kaletra</td>
    <td>Protease inhibitors
     <break/>Ritonavir is also a cytochrome P450 and P-gp inhibitor
    </td>
    <td>HIV</td>
   </tr>
   <tr>
    <td>Oseltamivir</td>
    <td>Tamiflu</td>
    <td>Inhibits viral neuraminidase and blocks the release of viral particles from host cells</td>
    <td>Influenza</td>
   </tr>
   <tr>
    <td>Remdesivir</td>
    <td>–</td>
    <td>Nucleotide analog inhibitor of RNA-dependent RNA polymerase (RdRp)</td>
    <td>Ebola virus</td>
   </tr>
   <tr>
    <td>Umifenovir</td>
    <td>Arbidol</td>
    <td>Viral fusion inhibition with the targeted membrane</td>
    <td>Influenza,
     <break/>SARS-CoV
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <hr/>
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <bold>Various well-known drugs</bold>
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <hr/>
    </td>
   </tr>
   <tr>
    <td>Azithromycin</td>
    <td>Zithromax, Azithrocin, others</td>
    <td>Inhibition translation of mRNA</td>
    <td>Macrolide antibiotic</td>
   </tr>
   <tr>
    <td>Carrimycin</td>
    <td>–</td>
    <td>Inhibition translation of mRNA</td>
    <td>Macrolide antibiotic</td>
   </tr>
   <tr>
    <td>Doxycycline</td>
    <td>Doxylin, others</td>
    <td>Inhibition bacterial protein synthesis</td>
    <td>Tetracycline antibiotic</td>
   </tr>
   <tr>
    <td>Chloroquine and hydroxychloroquine</td>
    <td>Aralen, Plaquenil, Quineprox, others</td>
    <td>Increase of lysosomal pH in antigen-presenting cells</td>
    <td>Malaria, systemic lupus erythematosus</td>
   </tr>
   <tr>
    <td>Nitazoxanide</td>
    <td>Alinia, Nizonide, and others</td>
    <td>Inhibition of the pyruvate: ferredoxin/flavodoxin oxidoreductase cycle</td>
    <td>Broad-spectrum antiparasitic</td>
   </tr>
   <tr>
    <td>Losartan
     <break/>Valsartan
    </td>
    <td>Cozaar, others</td>
    <td>Competitive angiotensin II receptor type 1 antagonist</td>
    <td>Hypertension</td>
   </tr>
   <tr>
    <td>Tetrandrine</td>
    <td>–</td>
    <td>Calcium channel blocker</td>
    <td>Hypertension</td>
   </tr>
   <tr>
    <td>Spironolactone</td>
    <td>Aldactone, others</td>
    <td>Potassium-sparing diuretic</td>
    <td>Hypertension</td>
   </tr>
   <tr>
    <td>Bromhexine</td>
    <td>Bisolvon, others</td>
    <td>Increasing lysosomal activity</td>
    <td>Mucolytic</td>
   </tr>
   <tr>
    <td>Dornase alfa</td>
    <td>Pulmozyme</td>
    <td>Recombinant human deoxyribonuclease I</td>
    <td>Cystic fibrosis</td>
   </tr>
   <tr>
    <td>Dexmedetomidine</td>
    <td>Precedex</td>
    <td>Selective alpha-2 adrenoceptor agonist</td>
    <td>Sedation</td>
   </tr>
   <tr>
    <td>Fluoxetine</td>
    <td>Prozac, others</td>
    <td>Selective serotonin reuptake inhibitor</td>
    <td>Antidepressant</td>
   </tr>
   <tr>
    <td colspan="4">
     <hr/>
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <bold>Immunosuppressors</bold>
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <hr/>
    </td>
   </tr>
   <tr>
    <td>Ruxolitinib</td>
    <td>Jakafi, Jakavi</td>
    <td>JAK inhibition</td>
    <td>Rheumatoid arthritis</td>
   </tr>
   <tr>
    <td>Tocilizumab</td>
    <td>Actemra, RoActemra</td>
    <td>Interleukin-6 receptor antagonist</td>
    <td>Rheumatoid arthritis</td>
   </tr>
   <tr>
    <td>Eculizumab</td>
    <td>Soliris</td>
    <td>Monoclonal antibody against C5</td>
    <td>Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, neuromyelitis optica</td>
   </tr>
   <tr>
    <td>Methylprednisolone</td>
    <td>Medrol, Meprolone, others</td>
    <td>Inhibition of proinflammatory cytokine production</td>
    <td>Inflammation, immune system disorders</td>
   </tr>
   <tr>
    <td>Dexamethasone</td>
    <td>Dexasone, Decadron, others</td>
    <td>Inhibition of proinflammatory cytokine production</td>
    <td>Inflammation, immune system disorders</td>
   </tr>
   <tr>
    <td>Budesonide</td>
    <td>Pulmicort, others</td>
    <td>Inhibition of proinflammatory cytokine production</td>
    <td>Asthma</td>
   </tr>
   <tr>
    <td colspan="4">
     <hr/>
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <bold>Immunomodulators</bold>
    </td>
   </tr>
   <tr>
    <td colspan="4">
     <hr/>
    </td>
   </tr>
   <tr>
    <td>Camostat</td>
    <td>Foipan</td>
    <td>Inhibition of the transmembrane protease, serine 2 enzyme</td>
    <td>Chronic pancreatitis</td>
   </tr>
   <tr>
    <td>Interferons (IFN)</td>
    <td>IFN alfa-1b (Pegasys), IFN alfa-2b (Intron-A), IFN beta-1a (Avonex, Rebif), IFN beta-1b (Betaseron, Extavia)</td>
    <td>Initiation of JAK-STAT signaling cascades</td>
    <td>HBV, HCV, various autoimmune disorders, and cancers</td>
   </tr>
   <tr>
    <td>Sargramostim</td>
    <td>Leukine</td>
    <td>Recombinant granulocyte macrophage colony-stimulating factor</td>
    <td>Non-Hodgkin lymphoma, acute lymphocytic leukemia</td>
   </tr>
   <tr>
    <td>Lenalidomide</td>
    <td>Revlimid</td>
    <td>Induces tumor cell apoptosis</td>
    <td>Multiple myeloma</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>P-gp, P-glycoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.</p>
  </fn>
 </table-wrap-foot>
 <table-wrap-foot>
  <fn id="tblfn1">
   <label>a</label>
   <p id="ntpara0020">Properties of repurposed drugs for COVID-19 are comprehensively described elsewhere (
    <xref rid="bib36" ref-type="bibr">Lythgoe and Middleton, 2020</xref>) and are outlined briefly here.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
